Charles Mount, MD
Dermatology · Pittsburgh, PANPI 1598962078
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,137 of the $188,943 with a category attached, or 83.2%. AbbVie accounts for 73.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $51,017 and has fallen 68.7% since, to $15,978 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 728 payments — averaging $259.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$139K
- Novartis$24K
- Bristol Myers Squibb$12K
- Regeneron Healthcare Solutions, Inc.$3K
- UCB, Inc.$2K
- Johnson & Johnson$2K
- plus $6K from 23 others
What the payments were for
- Consulting fees$10,0885%
- Speaking & faculty fees$157,13783%
- Travel & lodging$5,5363%
- Food & beverage$16,0058%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 297 | $139,193 |
| Novartis | 43 | $24,341 |
| Bristol Myers Squibb | 19 | $12,161 |
| Regeneron Healthcare Solutions, Inc. | 18 | $2,818 |
| UCB, Inc. | 28 | $2,179 |
| Johnson & Johnson | 136 | $2,134 |
| Amgen | 3 | $2,032 |
| Galderma Laboratories, L.p. | 59 | $752 |
| Sanofi | 27 | $668 |
| E.r. Squibb & Sons, L.L.C. | 48 | $610 |
| AstraZeneca | 10 | $528 |
| Journey Medical Corporation | 8 | $446 |
| Incyte Corporation | 6 | $220 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $122 |
| Arcutis Biotherapeutics, Inc. | 1 | $112 |
| Kyowa Kirin, Inc. | 1 | $95 |
| Regeneron | 2 | $84 |
| LEO Pharma Inc. | 3 | $78 |
| Sun Pharmaceutical Industries Inc. | 3 | $74 |
| Dermavant Sciences, Inc. | 3 | $45 |
| Lilly USA, LLC | 2 | $42 |
| Merck | 2 | $37 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Pfizer | 2 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $26 |
| Organon | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$188,943 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 57 | $417,838 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $228,318 |
| Dupixent PenDupilumab | 59 | $222,282 |
| RemicadeInfliximab | 13 | $207,663 |
| OtezlaApremilast | 25 | $105,757 |
| OpzeluraRuxolitinib Phosphate | 16 | $30,568 |
| Acitretin | 69 | $23,094 |
| Mycophenolic AcidMycophenolate Sodium | 16 | $9,131 |
| Fluorouracil | 119 | $8,615 |
| Clobetasol Propionate | 141 | $6,868 |
| Ketoconazole | 259 | $5,838 |
| Hydroxychloroquine Sulfate | 119 | $4,957 |
| Tacrolimus | 43 | $4,498 |
| Mycophenolate Mofetil | 35 | $3,948 |
| Doxycycline Hyclate | 125 | $3,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $139,193 | $417,83857 claims |
| Johnson & JohnsonRemicade | $2,134 | $207,66313 claims |
| AmgenOtezla | $2,032 | $105,75725 claims |
| Incyte CorporationOpzelura | $220 | $30,56816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.
Other dermatology in Pittsburgh
- Neil NirenPittsburgh$574K
- Laura FerrisPittsburgh$502K
- Oleg AkilovPittsburgh$409K
- Joe TungPittsburgh$404K
- Timothy PattonPittsburgh$72K
- Daniel KaplanPittsburgh$46K
- Hassane ZarourPittsburgh$44K
- Scott GottliebExton$2.1M
- Douglas KressWexford$2M
- Stephen HessPhiladelphia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.